1.

Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands

2.

Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands

3.

Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands

4.

Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands

1.

Incidence of ocular side effects of topical beta blockers in the Netherlands

2.

Incidence of ocular side effects of topical beta blockers in the Netherlands

3.

Incidence of ocular side effects of topical beta blockers in the Netherlands

4.

Incidence of ocular side effects of topical beta blockers in the Netherlands

1.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

2.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

3.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

4.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

5.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

6.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

7.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

8.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

9.

The incidence of visual impairment due to retinopathy of prematurity (ROP) and concomitant disabilities in the Netherlands: a 30 year overview

1.

The Dutch Version of the Behavior Rating Inventory of Executive Function-2 (BRIEF-2)

1.

Measuring Anxiety Symptoms – Psychometric Properties of the Dutch Version of the Lehrer–Woolfolk Anxiety Scale Questionnaire

2.

Measuring Anxiety Symptoms – Psychometric Properties of the Dutch Version of the Lehrer–Woolfolk Anxiety Scale Questionnaire

1.

Detecting Symptom Overreporting – Equivalence of the Dutch and German Self-Report Symptom Inventory

1.

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab

2.

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab

3.

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab

4.

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab

1.

Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

2.

Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

3.

Maternal Serum VEGF Predicts Abnormally Invasive Placenta Better than NT-proBNP: a Multicenter Case-Control Study

1.

Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes

2.

Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes

3.

Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes

4.

Multicentre analysis of hyperglycaemic hyperosmolar state and diabetic ketoacidosis in type 1 and type 2 diabetes